Ratings C.Q. Pharmaceutical Holding Co., Ltd.

Equities

000950

CNE0000010K0

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
6.01 ^CNY	-0.83%		+6.56%	+20.93%

May. 06	China Grants Drug Registration Certificate to C.Q. Pharmaceutical's Anti-Inflammatory Drug	MT
Apr. 26	C.Q. Pharmaceutical Holding Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company's profit outlook over the next few years is a strong asset.
Its low valuation, with P/E ratio at 9.39 and 8.07 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
C.Q. PHARMACEUTICAL HOLDING CO., LTD.	+20.93%	1.45B	-
MCKESSON CORPORATION	+20.35%	73.31B	C+
CARDINAL HEALTH, INC.	-4.40%	23.98B	C+
SINOPHARM GROUP CO. LTD.	+4.89%	8.8B	C
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+9.21%	8.6B	B
HUADONG MEDICINE CO., LTD	-20.79%	8.07B	B-
EBOS GROUP LIMITED	-1.41%	4.16B	B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+12.27%	4.14B	B+
GALENICA AG	-2.75%	3.88B	B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+23.24%	3.72B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes